It was reported that a fever occurred.On (b)(6) 2021, the patient was enrolled into the (b)(6) study and the treatment with therasphere was performed on same day.1.67 gbq was administered through vial-1 and 1.51 gbq was administered through vial-2.Total dose of 3.18 gbq was administered to the patient.Post-treatment macroaggregated albumin (maa) imaging documented a strong uptake of maa on tumors, doses to perfused liver was 100 gy and dose to perfused tumor was 151 gy.On (b)(6) 2021, 50 days post therasphere administration, the patient developed fever (39.5 celsius) and was hospitalized for further evaluation and treatment on (b)(6) 2021.The patient was treated with concomitant medication and the event was considered resolved on (b)(6) 2021.Patient was discharged on the same day.This event is listed as causally related to therasphere.No further patient events were reported.No other information is known at this time.This report will be updated should additional information become available.
|